Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
Work
Year: 2023
Type: article
Abstract: Breast cancer (BC) is one of the most common malignant tumors in women. In addition, human epidermal growth factor receptor 2-positive (HER2+) BC is overexpressed in 25% of BC patients, resulting in t... more
Source: Frontiers in Oncology
Institutions Zhejiang Chinese Medical University, Hangzhou Cancer Hospital, Zhejiang University, Hangzhou First People's Hospital
Cites: 35
Cited by: 2
Related to: 10
FWCI: 0.585
Citation percentile (by year/subfield): 78.64
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal No poverty
Open Access status: gold
APC paid (est): $2,950